|
US3896111A
(en)
|
1973-02-20 |
1975-07-22 |
Research Corp |
Ansa macrolides
|
|
US4151042A
(en)
|
1977-03-31 |
1979-04-24 |
Takeda Chemical Industries, Ltd. |
Method for producing maytansinol and its derivatives
|
|
US4137230A
(en)
|
1977-11-14 |
1979-01-30 |
Takeda Chemical Industries, Ltd. |
Method for the production of maytansinoids
|
|
US4307016A
(en)
|
1978-03-24 |
1981-12-22 |
Takeda Chemical Industries, Ltd. |
Demethyl maytansinoids
|
|
US4265814A
(en)
|
1978-03-24 |
1981-05-05 |
Takeda Chemical Industries |
Matansinol 3-n-hexadecanoate
|
|
JPS5562090A
(en)
|
1978-10-27 |
1980-05-10 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
|
US4256746A
(en)
|
1978-11-14 |
1981-03-17 |
Takeda Chemical Industries |
Dechloromaytansinoids, their pharmaceutical compositions and method of use
|
|
JPS55164687A
(en)
|
1979-06-11 |
1980-12-22 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
|
JPS5566585A
(en)
|
1978-11-14 |
1980-05-20 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
|
JPS55102583A
(en)
|
1979-01-31 |
1980-08-05 |
Takeda Chem Ind Ltd |
20-acyloxy-20-demethylmaytansinoid compound
|
|
US4515894A
(en)
|
1979-03-20 |
1985-05-07 |
Ortho Pharmaceutical Corporation |
Hybrid cell line for producing monoclonal antibody to human T cells
|
|
US4363799A
(en)
|
1979-03-20 |
1982-12-14 |
Ortho Pharmaceutical Corporation |
Monoclonal antibody to human T cells, and methods for preparing same
|
|
US4657760A
(en)
|
1979-03-20 |
1987-04-14 |
Ortho Pharmaceutical Corporation |
Methods and compositions using monoclonal antibody to human T cells
|
|
JPS55162791A
(en)
|
1979-06-05 |
1980-12-18 |
Takeda Chem Ind Ltd |
Antibiotic c-15003pnd and its preparation
|
|
JPS55164685A
(en)
|
1979-06-08 |
1980-12-22 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
|
JPS55164686A
(en)
|
1979-06-11 |
1980-12-22 |
Takeda Chem Ind Ltd |
Novel maytansinoid compound and its preparation
|
|
US4309428A
(en)
|
1979-07-30 |
1982-01-05 |
Takeda Chemical Industries, Ltd. |
Maytansinoids
|
|
JPS5645483A
(en)
|
1979-09-19 |
1981-04-25 |
Takeda Chem Ind Ltd |
C-15003phm and its preparation
|
|
EP0028683A1
(en)
|
1979-09-21 |
1981-05-20 |
Takeda Chemical Industries, Ltd. |
Antibiotic C-15003 PHO and production thereof
|
|
JPS5645485A
(en)
|
1979-09-21 |
1981-04-25 |
Takeda Chem Ind Ltd |
Production of c-15003pnd
|
|
US4675386A
(en)
|
1979-11-27 |
1987-06-23 |
Regents Of The University Of California |
Monoclonal antibody methods and compositions specific for single antigens in antigen aggregates
|
|
WO1982001188A1
(en)
|
1980-10-08 |
1982-04-15 |
Takeda Chemical Industries Ltd |
4,5-deoxymaytansinoide compounds and process for preparing same
|
|
US4450254A
(en)
|
1980-11-03 |
1984-05-22 |
Standard Oil Company |
Impact improvement of high nitrile resins
|
|
US4313946A
(en)
|
1981-01-27 |
1982-02-02 |
The United States Of America As Represented By The Secretary Of Agriculture |
Chemotherapeutically active maytansinoids from Trewia nudiflora
|
|
US4315929A
(en)
|
1981-01-27 |
1982-02-16 |
The United States Of America As Represented By The Secretary Of Agriculture |
Method of controlling the European corn borer with trewiasine
|
|
JPS57192389A
(en)
|
1981-05-20 |
1982-11-26 |
Takeda Chem Ind Ltd |
Novel maytansinoid
|
|
US4880935A
(en)
|
1986-07-11 |
1989-11-14 |
Icrf (Patents) Limited |
Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
|
|
DE3852304T3
(de)
|
1987-03-02 |
1999-07-01 |
Enzon Labs Inc., Piscataway, N.J. |
Organismus als Träger für "Single Chain Antibody Domain (SCAD)".
|
|
US5770701A
(en)
|
1987-10-30 |
1998-06-23 |
American Cyanamid Company |
Process for preparing targeted forms of methyltrithio antitumor agents
|
|
US5606040A
(en)
|
1987-10-30 |
1997-02-25 |
American Cyanamid Company |
Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
|
|
JPH03503887A
(ja)
|
1988-02-03 |
1991-08-29 |
エクソウマ コーポレーション |
自己免疫疾患に対する抗ｔ細胞イムノトキシンの治療的使用
|
|
IL106992A
(en)
|
1988-02-11 |
1994-06-24 |
Bristol Myers Squibb Co |
Acylhydrazone derivatives of anthracycline and methods for their preparation
|
|
US6010902A
(en)
|
1988-04-04 |
2000-01-04 |
Bristol-Meyers Squibb Company |
Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US5413923A
(en)
|
1989-07-25 |
1995-05-09 |
Cell Genesys, Inc. |
Homologous recombination for universal donor cells and chimeric mammalian hosts
|
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
CA2026147C
(en)
|
1989-10-25 |
2006-02-07 |
Ravi J. Chari |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
EP1690934A3
(en)
|
1990-01-12 |
2008-07-30 |
Abgenix, Inc. |
Generation of xenogeneic antibodies
|
|
US5427908A
(en)
|
1990-05-01 |
1995-06-27 |
Affymax Technologies N.V. |
Recombinant library screening methods
|
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
|
US5814318A
(en)
|
1990-08-29 |
1998-09-29 |
Genpharm International Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
|
US5633425A
(en)
|
1990-08-29 |
1997-05-27 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
|
US5661016A
(en)
|
1990-08-29 |
1997-08-26 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
|
ATE300615T1
(de)
|
1990-08-29 |
2005-08-15 |
Genpharm Int |
Transgene mäuse fähig zur produktion heterologer antikörper
|
|
US5625126A
(en)
|
1990-08-29 |
1997-04-29 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
|
IT1249051B
(it)
*
|
1991-02-26 |
1995-02-11 |
Italfarmaco Spa |
Immunotossina da anticorpi monoclonali anti-cd5
|
|
AU1771192A
(en)
|
1991-03-12 |
1992-10-21 |
Biogen, Inc. |
Monoclonal antibodies recognizing lymphocyte function associated antigen-3
|
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
WO1993006217A1
(en)
|
1991-09-19 |
1993-04-01 |
Genentech, Inc. |
EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
|
|
US6162432A
(en)
|
1991-10-07 |
2000-12-19 |
Biogen, Inc. |
Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
|
|
US6764681B2
(en)
|
1991-10-07 |
2004-07-20 |
Biogen, Inc. |
Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
|
|
US6146850A
(en)
|
1991-11-04 |
2000-11-14 |
Xoma Corporation |
Proteins encoding gelonin sequences
|
|
US5837491A
(en)
|
1991-11-04 |
1998-11-17 |
Xoma Corporation |
Polynucleotides encoding gelonin sequences
|
|
US5621083A
(en)
|
1991-11-04 |
1997-04-15 |
Xoma Corporation |
Immunotoxins comprising ribosome-inactivating proteins
|
|
ES2341666T3
(es)
|
1991-12-02 |
2010-06-24 |
Medimmune Limited |
Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
|
|
EP1291360A1
(en)
*
|
1991-12-13 |
2003-03-12 |
Xoma Corporation |
Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
|
|
US5869619A
(en)
*
|
1991-12-13 |
1999-02-09 |
Xoma Corporation |
Modified antibody variable domains
|
|
US5622929A
(en)
|
1992-01-23 |
1997-04-22 |
Bristol-Myers Squibb Company |
Thioether conjugates
|
|
ES2149768T3
(es)
|
1992-03-25 |
2000-11-16 |
Immunogen Inc |
Conjugados de agentes enlazantes de celulas derivados de cc-1065.
|
|
US5635483A
(en)
|
1992-12-03 |
1997-06-03 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Tumor inhibiting tetrapeptide bearing modified phenethyl amides
|
|
US5780588A
(en)
|
1993-01-26 |
1998-07-14 |
Arizona Board Of Regents |
Elucidation and synthesis of selected pentapeptides
|
|
US5817311A
(en)
|
1993-03-05 |
1998-10-06 |
Universite Catholique De Louvain |
Methods of inhibiting T-cell medicated immune responses with LO-CD2a-specific antibodies
|
|
US7592006B1
(en)
|
1993-03-05 |
2009-09-22 |
Université Catholique de Louvain |
Composition comprising the LO-CD2a antibody
|
|
US5730979A
(en)
|
1993-03-05 |
1998-03-24 |
Universite Catholique Delouvain |
LO-CD2a antibody and uses thereof for inhibiting T cell activation and proliferation
|
|
DE69428272T2
(de)
|
1993-03-05 |
2002-06-27 |
Universite Catholique De Louvain, Louvair La Neuve |
Lo-cd2a antikörper und dessen verwendung zur inhibition von t-zell-aktivierung und -wachstum
|
|
US5951983A
(en)
|
1993-03-05 |
1999-09-14 |
Universite Catholique De Louvain |
Methods of inhibiting T cell mediated immune responses with humanized LO-CD2A-specific antibodies
|
|
DE4312916C2
(de)
|
1993-04-14 |
1995-03-23 |
Fresenius Ag |
Arzneimittel zur Behandlung von Immunreaktionen
|
|
US6214345B1
(en)
|
1993-05-14 |
2001-04-10 |
Bristol-Myers Squibb Co. |
Lysosomal enzyme-cleavable antitumor drug conjugates
|
|
US5795572A
(en)
|
1993-05-25 |
1998-08-18 |
Bristol-Myers Squibb Company |
Monoclonal antibodies and FV specific for CD2 antigen
|
|
EP0647450A1
(en)
|
1993-09-09 |
1995-04-12 |
BEHRINGWERKE Aktiengesellschaft |
Improved prodrugs for enzyme mediated activation
|
|
WO1995024217A1
(en)
|
1994-03-08 |
1995-09-14 |
Dana-Farber Cancer Institute |
Methods for modulating t cell unresponsiveness
|
|
US5773001A
(en)
|
1994-06-03 |
1998-06-30 |
American Cyanamid Company |
Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
|
|
US5789199A
(en)
|
1994-11-03 |
1998-08-04 |
Genentech, Inc. |
Process for bacterial production of polypeptides
|
|
US5663149A
(en)
|
1994-12-13 |
1997-09-02 |
Arizona Board Of Regents Acting On Behalf Of Arizona State University |
Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
|
|
US5840523A
(en)
|
1995-03-01 |
1998-11-24 |
Genetech, Inc. |
Methods and compositions for secretion of heterologous polypeptides
|
|
CA2219361C
(en)
|
1995-04-27 |
2012-02-28 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
EP0823941A4
(en)
|
1995-04-28 |
2001-09-19 |
Abgenix Inc |
HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
|
|
US5712374A
(en)
|
1995-06-07 |
1998-01-27 |
American Cyanamid Company |
Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
|
|
WO1996041608A2
(en)
|
1995-06-07 |
1996-12-27 |
Thera Pro |
Pyrularia thionin containing immunotoxins and immunotoxin-like conjugates
|
|
US5714586A
(en)
|
1995-06-07 |
1998-02-03 |
American Cyanamid Company |
Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
|
|
ATE234635T1
(de)
|
1995-12-22 |
2003-04-15 |
Bristol Myers Squibb Co |
Verzweigte hydrazongruppen enthaltende kuppler
|
|
US6218519B1
(en)
|
1996-04-12 |
2001-04-17 |
Pro-Neuron, Inc. |
Compounds and methods for the selective treatment of cancer and bacterial infections
|
|
US6764688B2
(en)
|
1996-09-03 |
2004-07-20 |
Kaneka Corporation |
Method for inducing immunosuppressive cells and a culture device to be used therefor
|
|
EP0961619A4
(en)
|
1996-09-27 |
2001-09-26 |
Bristol Myers Squibb Co |
HYDROLYSABLE DRUGS FOR THE RELEASE OF ANTI-CANCER DRUGS IN METASTATIC CELLS
|
|
US5916771A
(en)
|
1996-10-11 |
1999-06-29 |
Abgenix, Inc. |
Production of a multimeric protein by cell fusion method
|
|
US6759509B1
(en)
|
1996-11-05 |
2004-07-06 |
Bristol-Myers Squibb Company |
Branched peptide linkers
|
|
EP1500329B1
(en)
|
1996-12-03 |
2012-03-21 |
Amgen Fremont Inc. |
Human antibodies that specifically bind human TNF alpha
|
|
US6849258B1
(en)
|
1997-07-18 |
2005-02-01 |
Universite Catholique De Louvain |
LO-CD2a antibody and uses thereof for inhibiting T cell activation and proliferation
|
|
US6358506B1
(en)
|
1997-11-05 |
2002-03-19 |
University Of Southern California |
Use of cytokines and mitogens to inhibit pathological immune responses
|
|
US6558662B2
(en)
|
1997-11-14 |
2003-05-06 |
The General Hospital Corporation |
Treatment of hematologic disorders
|
|
US20060051355A1
(en)
|
1998-03-23 |
2006-03-09 |
Van Oosterhout Ypke V |
Methods and means for the treatment of immune-related diseases
|
|
HK1040052B
(zh)
|
1998-05-22 |
2006-09-15 |
第一制药株式会社 |
药物复合物
|
|
US7157418B1
(en)
|
1998-07-22 |
2007-01-02 |
Osprey Pharmaceuticals, Ltd. |
Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
|
|
WO2000045842A2
(en)
|
1999-02-04 |
2000-08-10 |
The General Hospital Corporation |
Methods for human allografting
|
|
US6268488B1
(en)
|
1999-05-25 |
2001-07-31 |
Barbas, Iii Carlos F. |
Prodrug activation using catalytic antibodies
|
|
US6541611B1
(en)
|
1999-06-18 |
2003-04-01 |
Universite Catholique De Louvain |
LO-CD2b antibody
|
|
US20040052793A1
(en)
|
2001-02-22 |
2004-03-18 |
Carter Paul J. |
Caspase activivated prodrugs therapy
|
|
US6333410B1
(en)
|
2000-08-18 |
2001-12-25 |
Immunogen, Inc. |
Process for the preparation and purification of thiol-containing maytansinoids
|
|
US20040018194A1
(en)
|
2000-11-28 |
2004-01-29 |
Francisco Joseph A. |
Recombinant anti-CD30 antibodies and uses thereof
|
|
WO2002098370A2
(en)
|
2001-03-02 |
2002-12-12 |
Medimmune, Inc. |
Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
|
|
EP1243276A1
(en)
|
2001-03-23 |
2002-09-25 |
Franciscus Marinus Hendrikus De Groot |
Elongated and multiple spacers containing activatible prodrugs
|
|
US6884869B2
(en)
|
2001-04-30 |
2005-04-26 |
Seattle Genetics, Inc. |
Pentapeptide compounds and uses related thereto
|
|
US6441163B1
(en)
|
2001-05-31 |
2002-08-27 |
Immunogen, Inc. |
Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
|
|
US7091186B2
(en)
|
2001-09-24 |
2006-08-15 |
Seattle Genetics, Inc. |
p-Amidobenzylethers in drug delivery agents
|
|
US6716821B2
(en)
|
2001-12-21 |
2004-04-06 |
Immunogen Inc. |
Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
|
|
US20080254027A1
(en)
*
|
2002-03-01 |
2008-10-16 |
Bernett Matthew J |
Optimized CD5 antibodies and methods of using the same
|
|
AU2003294210A1
(en)
|
2002-07-31 |
2004-05-04 |
Seattle Genetics, Inc |
Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders
|
|
WO2004022097A1
(en)
|
2002-09-05 |
2004-03-18 |
Medimmune, Inc. |
Methods of preventing or treating cell malignancies by administering cd2 antagonists
|
|
US8088387B2
(en)
|
2003-10-10 |
2012-01-03 |
Immunogen Inc. |
Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
|
|
US7276497B2
(en)
|
2003-05-20 |
2007-10-02 |
Immunogen Inc. |
Cytotoxic agents comprising new maytansinoids
|
|
HRP20100334T1
(hr)
|
2003-09-18 |
2010-07-31 |
Novartis Ag |
Terapeutska humanizirana antitijela protiv cd45-izoforma
|
|
US7498298B2
(en)
|
2003-11-06 |
2009-03-03 |
Seattle Genetics, Inc. |
Monomethylvaline compounds capable of conjugation to ligands
|
|
EP1718667B1
(en)
|
2004-02-23 |
2013-01-09 |
Genentech, Inc. |
Heterocyclic self-immolative linkers and conjugates
|
|
KR101270829B1
(ko)
|
2004-09-23 |
2013-06-07 |
제넨테크, 인크. |
시스테인 유전자조작 항체 및 접합체
|
|
EP1661584A1
(en)
|
2004-11-26 |
2006-05-31 |
Heinz Dr. Faulstich |
Use of conjugates of amatoxins and phallotoxins with macromolecules for cancer and inflammation therapy
|
|
ES2371085T3
(es)
|
2006-05-27 |
2011-12-27 |
Faulstich, Heinz, Dr. |
Utilización de conjugados de amatoxinas o falotoxinas con macromoléculas para la terapia tumoral y de la inflamación.
|
|
ES2882360T3
(es)
|
2006-11-03 |
2021-12-01 |
Univ Leland Stanford Junior |
Inmunoempobrecimiento selectivo de un nicho de células madre endógenas para injerto
|
|
WO2008121160A2
(en)
*
|
2006-11-21 |
2008-10-09 |
Xencor, Inc. |
Optimized antibodies that target cd5
|
|
ITBO20070242A1
(it)
|
2007-04-03 |
2008-10-04 |
Gsg Int Spa |
Profilato per serramenti scorrevoli, metodo per la realizzazione del profilato, e serramento ottenuto con il profilato stesso.
|
|
KR20200058590A
(ko)
|
2008-04-30 |
2020-05-27 |
이뮤노젠 아이엔씨 |
가교제 및 그 용도
|
|
MX2011000970A
(es)
|
2008-08-29 |
2011-03-15 |
Symphogen As |
Anticuerpos anti-cd5.
|
|
US9233173B2
(en)
|
2009-04-08 |
2016-01-12 |
Deutsches Krebsforschungszentrum |
Amatoxin-armed therapeutic cell surface binding components designed for tumour therapy
|
|
JP2012523383A
(ja)
|
2009-04-08 |
2012-10-04 |
ファウルシュティヒ，ハインツ |
がんの治療のためのアマトキシンと複合体形成した標的結合部分
|
|
EP2430051B1
(en)
|
2009-05-14 |
2016-03-23 |
Institut National de la Santé et de la Recherche Medicale |
Compositions containing antibodies for treating cd5+ hla-dr+ b or t cell related diseases
|
|
NZ607906A
(en)
*
|
2010-08-18 |
2015-11-27 |
Theresa Deisher |
Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues
|
|
KR20130105652A
(ko)
|
2010-09-08 |
2013-09-25 |
예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 |
안정하고 장기간의 인그래프트먼트를 위한 면역억제 약물의 조합
|
|
ES2402254T3
(es)
|
2010-09-30 |
2013-04-30 |
Heidelberg Pharma Ag |
Conjugados de amatoxinas con ligadores mejorados
|
|
EP2497499A1
(en)
|
2011-03-10 |
2012-09-12 |
Heidelberg Pharma GmbH |
Amatoxin-conjugates with improved linkages
|
|
MX370404B
(es)
|
2011-12-22 |
2019-12-11 |
Yeda Res & Dev |
Uso de una terapia de combinación para inducir un injerto estable y a largo plazo.
|
|
WO2013116307A1
(en)
*
|
2012-01-30 |
2013-08-08 |
Mount Sinai School Of Medicine |
Method for programming differentiated cells into hematopoietic stem cells
|
|
US20130280282A1
(en)
|
2012-04-24 |
2013-10-24 |
Daiichi Sankyo Co., Ltd. |
Dr5 ligand drug conjugates
|
|
US9504756B2
(en)
|
2012-05-15 |
2016-11-29 |
Seattle Genetics, Inc. |
Self-stabilizing linker conjugates
|
|
EP2684865A1
(en)
|
2012-07-13 |
2014-01-15 |
Heidelberg Pharma GmbH |
Methods for synthesizing amatoxin building block and amatoxins
|
|
US20150218220A1
(en)
|
2012-09-12 |
2015-08-06 |
Brian Alan MENDELSOHN |
Amatoxin derivatives and cell-permeable conjugates thereof as inhibitors of rna polymerase
|
|
ES2732574T3
(es)
|
2012-11-30 |
2019-11-25 |
Novartis Ag |
Métodos para preparar conjugados a partir de proteínas que contienen disulfuro
|
|
JP2016516672A
(ja)
|
2013-02-28 |
2016-06-09 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
幹細胞を動員するための方法および組成物
|
|
EP2774624A1
(en)
|
2013-03-04 |
2014-09-10 |
Heidelberg Pharma GmbH |
Amatoxin derivatives
|
|
EP2968591A1
(en)
|
2013-03-15 |
2016-01-20 |
Novartis AG |
Cell proliferation inhibitors and conjugates thereof
|
|
JP6701077B2
(ja)
|
2013-12-19 |
2020-05-27 |
シアトル ジェネティックス， インコーポレイテッド |
標的化薬物結合体と使用するためのメチレンカルバメートリンカー
|
|
CN106456762A
(zh)
|
2014-05-20 |
2017-02-22 |
伊缪诺金公司 |
用于表征和治疗急性髓样白血病的方法
|
|
WO2016053107A1
(en)
|
2014-10-03 |
2016-04-07 |
Synaffix B.V. |
Sulfamide linker, conjugates thereof, and methods of preparation
|
|
EP3215519A1
(en)
*
|
2014-11-06 |
2017-09-13 |
Novartis AG |
Amatoxin derivatives and conjugates thereof as inhibitors of rna polymerase
|
|
JP6863900B2
(ja)
*
|
2015-03-09 |
2021-04-21 |
ハイデルベルク ファルマ リサーチ ゲゼルシャフト ミット ベシュレンクテル ハフツング |
新規アマトキシン−抗体コンジュゲート
|
|
HK1249534A1
(zh)
|
2015-04-06 |
2018-11-02 |
哈佛大学校长及研究员协会 |
用於非清髓性预处理的组合物和方法
|
|
EP3286225B1
(en)
|
2015-04-23 |
2020-07-01 |
Baylor College of Medicine |
Cd5 chimeric antigen receptor for adoptive t cell therapy
|
|
ES2887273T3
(es)
|
2015-06-29 |
2021-12-22 |
Immunogen Inc |
Anticuerpos anti-CD123 y conjugados y derivados de los mismos
|
|
US20170129128A1
(en)
|
2015-11-05 |
2017-05-11 |
Black & Decker Inc. |
Saw
|
|
US10723766B2
(en)
|
2015-11-27 |
2020-07-28 |
Heidelberg Pharma Research Gmbh |
Derivatives of gamma-amanitin
|
|
EP3222292A1
(en)
|
2016-03-03 |
2017-09-27 |
Heidelberg Pharma GmbH |
Amanitin conjugates
|
|
CA3016172C
(en)
|
2016-04-20 |
2024-03-12 |
Hangzhou Dac Biotech Co., Ltd |
Derivatives of amanita toxins and their conjugation to a cell binding molecule
|
|
US10464969B2
(en)
|
2016-05-05 |
2019-11-05 |
Novartis Ag |
Amatoxin derivatives and conjugates thereof as inhibitors of RNA polymerase
|
|
CN109641051A
(zh)
|
2016-06-17 |
2019-04-16 |
美真达治疗公司 |
用于耗尽细胞的组合物和方法
|
|
BR112018076306A2
(pt)
|
2016-06-17 |
2019-03-26 |
Magenta Therapeutics, Inc. |
composições e métodos para a supressão de células cd117+
|
|
US11446388B2
(en)
|
2016-12-23 |
2022-09-20 |
Heidelberg Pharma Research Gmbh |
Amanitin antibody conjugates
|
|
MX395639B
(es)
|
2017-01-20 |
2025-03-25 |
Heidelberg Pharma Res Gmbh |
Composiciones y métodos para el agotamiento de células cd137+.
|
|
CA3065126A1
(en)
|
2017-06-01 |
2018-12-06 |
Innovative Cellular Therapeutics CO., LTD. |
Chimeric antigen receptor cell preparation and uses thereof
|
|
WO2019030171A1
(en)
|
2017-08-07 |
2019-02-14 |
Heidelberg Pharma Gmbh |
NOVEL METHOD FOR SYNTHESIZING AMANITINES
|
|
CA3079897A1
(en)
|
2017-10-24 |
2019-05-02 |
Magenta Therapeutics, Inc. |
Compositions and methods for the depletion of cd117+ cells
|
|
WO2019108863A1
(en)
|
2017-11-29 |
2019-06-06 |
Magenta Therapeutics, Inc. |
Compositions and methods for the depletion of cd5+ cells
|
|
US10869888B2
(en)
|
2018-04-17 |
2020-12-22 |
Innovative Cellular Therapeutics CO., LTD. |
Modified cell expansion and uses thereof
|
|
CA3107383A1
(en)
|
2018-07-23 |
2020-01-30 |
Magenta Therapeutics, Inc. |
Use of anti-cd5 antibody drug conjugate (adc) in allogeneic cell therapy
|